BRD4-targeted therapy ABBV-744 clinical data No Further a Mystery
In Section A, individuals will receive distinctive doses and schedules of oral ABBV-744 pill to recognize Protected dosing routine. Added individuals will probably be enrolled on the recognized monotherapy dosign regimen. In Phase B, members will receive oral ruxolitinib and ABBV-744 will probably be given as "increase-on" therapy. In Section C, co